Active: Response to interferon beta therapy Clear all

GWAS 2020-11-04

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

Andlauer TFM, Link J et al.

BMC Med

Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) tha...

Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous)

Replicated

1145

Participants

N/A

Studies

Details PubMed

GWAS 2018-03-01

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF et al.

Mult Scler

Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies dir...

Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production)

361

Participants

N/A

Studies

Details PubMed

GWAS 2011-04-19

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S et al.

Pharmacogenomics J

Interferons-β (IFN-β) are the most widely used immunomodulatory drugs for treatment of multiple scle...

Response to interferon beta therapy

Replicated

1180

Participants

N/A

Studies

Details PubMed

GWAS 2009-08-01

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Comabella M, Craig DW et al.

Arch Neurol

Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS). How...

Response to interferon beta therapy

Replicated

200

Participants

N/A

Studies

Details PubMed

GWAS 2008-01-14

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Byun E, Caillier SJ et al.

Arch Neurol

Objective: To identify promising candidate genes linked to interindividual differences in the effica...

Response to interferon beta therapy

Replicated

287

Participants

N/A

Studies

Details PubMed

Title

Author

Journal

Disease/Trait

Date

Actions

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS.

Andlauer TFM, Link J et al.

BMC Med

Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies; IFNβ-1a subcutaneous)

2020-11-04

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF et al.

Mult Scler

Neutralising antibody response to interferon beta therapy in multiple sclerosis (time to production)

2018-03-01

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S et al.

Pharmacogenomics J

Response to interferon beta therapy

2011-04-19

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Comabella M, Craig DW et al.

Arch Neurol

Response to interferon beta therapy

2009-08-01

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Byun E, Caillier SJ et al.

Arch Neurol

Response to interferon beta therapy

2008-01-14